Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Merck
McKinsey
Colorcon
AstraZeneca
Moodys

Last Updated: January 27, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Trastuzumab emtansine

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Trastuzumab emtansine?

Trastuzumab emtansine is an investigational drug.

There have been 70 clinical trials for Trastuzumab emtansine. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2016.

The most common disease conditions in clinical trials are Breast Neoplasms, Stomach Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and Dana-Farber Cancer Institute.

There are thirty-three US patents protecting this investigational drug and six hundred and eighty-eight international patents.

Recent Clinical Trials for Trastuzumab emtansine
TitleSponsorPhase
A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alonexuexin hePhase 2
Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTCAC Camargo Cancer CenterPhase 2
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung CancerAstraZeneca UK LimitedPhase 1

See all Trastuzumab emtansine clinical trials

Clinical Trial Summary for Trastuzumab emtansine

Top disease conditions for Trastuzumab emtansine
Top clinical trial sponsors for Trastuzumab emtansine

See all Trastuzumab emtansine clinical trials

US Patents for Trastuzumab emtansine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Trastuzumab emtansine   Start Trial Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds Array BioPharma Inc. (Boulder, CO)   Start Trial
Trastuzumab emtansine   Start Trial Methods for the treatment of HER2 amplified cancer Pharmacyclics LLC (Sunnyvale, CA)   Start Trial
Trastuzumab emtansine   Start Trial Encapsulated agents and methods of making and using thereof University of Georgia Research Foundation, Inc. (Athens, GA)   Start Trial
Trastuzumab emtansine   Start Trial Binding molecules specific for HER3 and uses thereof MEDIMMUNE, LLC (Gaithersburg, MD)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Trastuzumab emtansine

Drugname Country Document Number Estimated Expiration Related US Patent
Trastuzumab emtansine Argentina 074052 2028-10-22   Start Trial
Trastuzumab emtansine Australia 2009308465 2028-10-22   Start Trial
Trastuzumab emtansine Australia 2015200511 2028-10-22   Start Trial
Trastuzumab emtansine Australia 2017268517 2028-10-22   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Medtronic
Mallinckrodt
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.